FEATURED EDITORIAL
How API manufacturers can assess and mitigate organic impurities and nitrosamines using risk-based strategies aligned with global regulatory expectations.
- The Future Of Continuous Is Integrated Manufacturing: The 4 Misconceptions About A Lean Process
- FDA Now A Supply-Chain Complication
- CDMO Selection: Start With The Relationship, Not The RFP
- Why FAT Should Confirm Alignment, Not Reveal Its Absence
- What Reliance, Annex 1, And AI Mean For The Future Of GMP
- A CMC Playbook For Leadership And Hiring
- Why Is Biopharma Left Out Of The U.S. Infrastructure Conversation?
GUEST COLUMNISTS
-
The Future Of Continuous Is Integrated Manufacturing: The 4 Misconceptions About A Lean Process
Pharmaceutical continuous manufacturing is an enabler of better manufacturing, but only when implemented with intention.
-
CDMO Selection: Start With The Relationship, Not The RFP
Friction often comes from unspoken expectations. Before production begins, treat the combined sponsor-CDMO group as one extended team and intentionally make “how we work together” visible.
-
Why FAT Should Confirm Alignment, Not Reveal Its Absence
In many aseptic fill/finish projects, the factory acceptance test (FAT) has become the first true integration test of the entire project. That is a problem. Here's how to flip that mindset.
-
What Reliance, Annex 1, And AI Mean For The Future Of GMP
EMA’s Brendan Cuddy explains how regulators are adapting oversight to global supply chains, new technologies, and growing operational complexity.
-
Applying Contamination Control By Design: A Practical Guide For CDMOs
This article addresses the three contamination control challenges that are specific to the CDMO environment, provides five practical steps any organization can act on now, and more.
-
Rethinking CQV In A Digital, Agile Manufacturing Landscape
While commissioning, qualification, and validation (CQV) remains foundational, the way it is planned and executed must evolve to keep pace with modern manufacturing realities.
-
Will FDA's One-Day Inspection Pilot Stand The Test Of Time?
FDA's complementary pilot could help weed through a persistent examination backlog, but uncertainty and upheaval in leadership at the top puts its future in question.
-
A Multi-Agent Audit Intelligence Framework For CDMO Quality Oversight
A Takeda quality executive demonstrates how a team of AI agents uses synthetic data to provide decision support ahead of CDMO audits.
PHARMA OUTSOURCING WHITE PAPERS
-
BioServices: Advanced Solutions For Cell And Gene Therapy Material Management
See how supply chain solutions like BioServices can help companies mitigate risk to their overall supply chain while saving valuable capital for the research of their lifesaving therapies.
-
AAV-Based Gene Editing For Huntington's Disease
LETI-101 uses AAV5 to deliver a compact CRISPR system for allele-selective editing of mutant HTT, showing promise as a one-time treatment for Huntington’s disease with strong preclinical safety and efficacy.
-
A Cell Line Development Platform Accelerating Timelines To Clinic
To support a seamless transition from early clinical studies through to commercial manufacturing, cell line expression systems must be carefully designed and selected based on several critical attributes.
-
Accelerated Development Of Solid Oral Dosage Formulation For IND Submission
This paper highlights how the roller compaction process not only enhances efficiency but also improves the scalability of solid oral dosage production, supporting rapid development for regulatory approval.
-
Leveraging Efficiency From CLD To Clinical Manufacturing Of mAbs
Discover how our efficient strategies can propel your mAb from discovery to clinical manufacturing in as little as 18 months.
-
How To Effectively Manage Local Affiliate Pharmacovigilance Outsourcing
Managing PV across dozens of markets strains even experienced safety teams. Learn about a framework that helps you maintain compliance, reduce risk, and scale confidently into new markets.
PHARMA OUTSOURCING APP NOTES & CASE STUDIES
- Improving Efficiency In Contamination Identification
- A Green Synthesis Process For A Growth Promoter Drug For Animals
- Mid-Sized Pharma Optimizes Local Affiliate Safety Operations
- Optimizing Bispecific Antibody Expression Via Multi-Omics Analysis And Vector Redesign
- Improve Speed To Market By Mitigating Vial And Stopper Incompatibility
NEWSLETTER ARCHIVE
REPORTING
PRODUCTS & SERVICES
ON-DEMAND WEBINARS
- Faster Clones, Simpler Process: What's Changing In CHO Expression?
- How Solid-State Science Solves Your Toughest API Challenges
- Building A Successful ICH Stability CoE Collaborating At Scale
- Accelerate Drug Development Through Strategic, Integrated Partnerships
- From Complexity To Confidence: Supporting Tech Transfer With A Prefillable Syringe System